Advances in the systemic therapy of malignant pleural mesothelioma

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Nature Clinical Practice Oncology

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ncponc1039PMID 18227828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma

  2008cited by this paper
• Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.

  2008cited by this paper
• Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)

  2007cited by this paper
• Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

  2007cited by this paper
• Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

  2007cited by this paper
• Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment

  2007cited by this paper
• Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway.

  2007cited by this paper
• Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma

  2007cited by this paper
• Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma

  2007cited by this paper
• Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

  2007cited by this paper
• BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

  2007cited by this paper
• Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.

  2006cited by this paper
• Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.

  2006cited by this paper
• Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM)

  2006cited by this paper
• In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

  2006cited by this paper
• Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Positron emission tomography predicts survival in malignant pleural mesothelioma.

  2006cited by this paper
• Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

  2006cited by this paper
• Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate

  2006cited by this paper
• Biology and management of malignant pleural mesothelioma.

  2006cited by this paper
• Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.

  2006cited by this paper
• Expression of Bcl-2 Family Members in Malignant Pleural Mesothelioma

  2006cited by this paper
• Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

  2006cited by this paper
• Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.

  2006cited by this paper
• Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.

  2006cited by this paper
• The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline

  2006cited by this paper
• Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.

  2006cited by this paper
• Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

  2006cited by this paper
• A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

  2006cited by this paper
• Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose

  2006cited by this paper
• The role of PET in the surgical management of malignant pleural mesothelioma.

  2005cited by this paper
• The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050

  2005cited by this paper
• Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

  2005cited by this paper
• Validation of Genomics-Based Prognostic Tests in Malignant Pleural Mesothelioma

  2005cited by this paper
• Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma.

  2005cited by this paper
• [Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) -- a case report].

  2005cited by this paper
• Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

  2005cited by this paper
• Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

  2005cited by this paper
• Inhibition of the Met Receptor in Mesothelioma

  2005cited by this paper
• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

  2005cited by this paper
• SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure.

  2005cited by this paper
• Human mesothelioma cells exhibit tumor cell–specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase

  2005cited by this paper
• New agents in the management of advanced mesothelioma.

  2005cited by this paper
• Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

  2005cited by this paper
• Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

  2005cited by this paper
• Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients

  2005cited by this paper
• Second-line-Behandlung des malignen Pleuramesothelioms mit Pemetrexed (Alimta®) - eine Kasuistik

  2005cited by this paper
• Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.

  2004cited by this paper
• Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma

  2004cited by this paper
• Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.

  2004cited by this paper
• Induction of Stem Cell Factor/c-Kit/Slug Signal Transduction in Multidrug-resistant Malignant Mesothelioma Cells*

  2004cited by this paper
• Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance

  2004cited by this paper
• The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.

  2004cited by this paper
• Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells

  2004cited by this paper
• Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.

  2004cited by this paper
• BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112

  2004cited by this paper
• Mesothelin

  2004cited by this paper
• Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells

  2004cited by this paper
• Efficacy of CD40 ligand gene therapy in malignant mesothelioma.

  2003cited by this paper
• Using gene expression ratios to predict outcome among patients with mesothelioma.

  2003cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.

  2002cited by this paper
• Phase II trial of ZD0473 as second-line therapy in mesothelioma.

  2002cited by this paper
• Ad-IFNγ Induces Antiproliferative and Antitumoral Responses in Malignant Mesothelioma

  2002cited by this paper
• Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma.

  2002cited by this paper
• Angiogenesis is an independent prognostic factor in malignant mesothelioma

  2001cited by this paper
• Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

  2001cited by this paper
• 5‐Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor

  2001cited by this paper
• Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

  2000cited by this paper
• Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

  2000cited by this paper
• VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours

  1999cited by this paper
• Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

  1999cited by this paper
• Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma.

  1999cited by this paper
• Tumor angiogenesis and recurrence in stage I non-small cell lung cancer.

  1999cited by this paper
• Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression

  1999cited by this paper
• Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax.

  1998cited by this paper
• Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

  1998cited by this paper
• Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.

  1998cited by this paper
• Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium

  1994cited by this paper
• Survival patterns for malignant mesothelioma: The seer experience

  1988cited by this paper

• Dual phase modeling of Chrysotile carcinogenesis from 3D cell transformation to orthotopic tumors

  2026cites this paper
• Synergistic Effect of Resveratrol and Paclitaxel in the Treatment of Malignant Pleural Mesothelioma

  2024cites this paper
• Clinical and cytologic finding of mesothelioma in situ with hemorrhagic malignant pleural effusion in a dog

  2024cites this paper
• Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report

  2023cites this paper
• Tasks and Experiences of the Prospective, Longitudinal, Multicenter MoMar (Molecular Markers) Study for the Early Detection of Mesothelioma in Individuals Formerly Exposed to Asbestos Using Liquid Biopsies

  2023cites this paper
• Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study

  2022cites this paper
• Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells

  2021cites this paper
• Communicating imaging findings in peritoneal mesothelioma: the impact of ‘PAUSE’ on surgical decision-making

  2021cites this paper
• Medical thoracoscopy in the diagnosis of pleural disease: a guide for the clinician

  2020cites this paper
• PRMT5 silencing selectively affects MTAP‐deleted mesothelioma: In vitro evidence of a novel promising approach

  2020cites this paper
• New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.

  2020cites this paper
• The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies

  2019cites this paper
• Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients

  2019cites this paper
• Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma

  2019cites this paper
• Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma

  2018cites this paper
• CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

  2018cites this paper
• Immunotherapy advances for mesothelioma

  2018cites this paper
• Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

  2018cites this paper
• Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma

  2018cites this paper
• FGF2 and EGF induce epithelial–mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal

  2018cites this paper
• Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

  2017cites this paper
• Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma

  2017cites this paper
• Apoptosis by [Pt(O,O′-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma

  2017cites this paper
• Immunotherapy advances for mesothelioma treatment

  2017cites this paper
• Mitochondrial association of MitoVES in MM cells was documented using its fluorescently tagged analogue. MitoVES caused apoptosis in MM cells by mitochondrial destabilization, resulting in the loss of mitochondrial membrane potential, generation of reactive oxygen species and destabilization of resp

  2017cites this paper
• Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

  2017cites this paper
• A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin

  2017cites this paper
• Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

  2017cites this paper
• Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis

  2017cites this paper
• CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

  2017cites this paper
• Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma

  2017cites this paper
• Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

  2016cites this paper
• Switching off malignant mesothelioma: exploiting the hypoxic microenvironment

  2016cites this paper
• Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma

  2016cites this paper
• Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972–2009

  2016cites this paper
• STRATEGIES TO ENHANCE EFFICACY OF ONCOLYTIC VIROTHERAPY

  2016cites this paper
• Malignant Pleural Mesothelioma : State of the art and recommendations

  2016cites this paper
• Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends

  2016cites this paper
• Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells

  2016cites this paper
• BIBLIOGRAPHIC REVIEW July 2016 Third Consensus Conference on Malignant Pleural Mesothelioma: State-of-the-art and recommendations

  2016cites this paper
• Consensus Report of the 2015 Weinman International Conference on Mesothelioma

  2016cites this paper
• Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review

  2015cites this paper
• Malignant pleural mesothelioma: new ideas needed

  2015cites this paper
• Malignant Peritoneal Mesothelioma Presenting as Ascites of Unknown Origin

  2015cites this paper
• Diagnosis and treatment of malignant pleural mesothelioma.

  2015cites this paper
• Inhibition of hedgehog signaling reduces the side population in human malignant mesothelioma cell lines

  2015cites this paper
• Diagnosis and Treatment of Malignant Pleural Mesothelioma

  2015cites this paper
• Medical and oncological management of malignant mesothelioma.

  2015cites this paper
• Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.

  2015cites this paper
• Diagnóstico y tratamiento del mesotelioma pleural maligno

  2015cites this paper
• Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies

  2015cites this paper
• Epigenetic therapy in lung cancer and mesothelioma

  2015cites this paper
• ASPECTOS DIAGNÓSTICOS Y TERAPÉUTICOS EN EL MESOTELIOMA PLEURAL MALIGNO

  2015cites this paper
• Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

  2014cites this paper
• ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.

  2014cites this paper
• Current issues in malignant pleural mesothelioma evaluation and management.

  2014cites this paper
• Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions

  2014cites this paper
• Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma

  2014cites this paper
• CARP-1 Functional Mimetics Are a Novel Class of Small Molecule Inhibitors of Malignant Pleural Mesothelioma Cells

  2014cites this paper
• Characterization of malignant pleural mesothelioma : possibilities for an individualized therapeutic arsenal

  2014cites this paper
• MicroRNA-126 Suppresses Mesothelioma Malignancy by Targeting IRS1 and Interfering with the Mitochondrial Function

  2014cites this paper
• ERCC 1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma

  2014cites this paper
• Mitochondrial targeting of α-tocopheryl succinate enhances its anti-mesothelioma efficacy

  2014cites this paper
• Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.

  2013cites this paper
• Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis

  2013cites this paper
• Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.

  2013cites this paper
• Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype.

  2013cites this paper
• Correction: BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma

  2013cites this paper
• Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter

  2013influential citation
• BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma

  2013cites this paper
• Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

  2013cites this paper
• The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.

  2013cites this paper
• A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine

  2013cites this paper
• Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy

  2013cites this paper
• Malignant Mesothelioma of the Pericardium: A Report of Two Different Presentations

  2013cites this paper
• The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.

  2013cites this paper
• Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.

  2012cites this paper
• BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma

  2012cites this paper
• Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients

  2012cites this paper
• Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.

  2012influential citation
• Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

  2012cites this paper
• Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma

  2012cites this paper
• Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma.

  2012cites this paper
• Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy

  2012cites this paper
• Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population-Based Study of 1686 Cases

  2012cites this paper
• Malignant pleural effusion: further translational research is crucial.

  2012cites this paper
• Case Study : Therapeutic Options for Managing Peritoneal Mesothelioma

  2012cites this paper
• Cancer Therapy : Preclinical CSPG 4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma

  2012cites this paper
• Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-Methylfunicone from Penicillium pinophilum and cisplatin

  2012cites this paper
• Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.

  2012cites this paper
• Malignant pleural effusion: tumor-host interactions unleashed.

  2012cites this paper
• Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2—dependent T-type Ca2+ channel opening

  2012cites this paper
• Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

  2012cites this paper
• The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.

  2012cites this paper
• COPD SIG: Poster Session 2

  2011cites this paper
• Advances in the biology of malignant pleural mesothelioma.

  2011cites this paper
• A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.

  2011cites this paper
• Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data

  2011cites this paper
• Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.

  2011cites this paper
• The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance

  2011cites this paper